Highlands Investments, a licensed cultivator of high-quality, low-cost medical grade cannabis, has secured its first significant Canna-TractTM customer – CBD Pharma Farms (Pty) Ltd (“CBD Pharma”). CBD Pharma is a South African CBD business with an off-take agreement to export CBD products to Europe.
“We are delighted that CBD Pharma chose to partner with Highlands to cultivate their cannabis,” says Highlands Investments Managing Director, Mark Corbett. “Having completed four successful harvests, we have fine-tuned our processes further and are skilled at growing, packaging and processing commercial volumes of premium flower.”
Canna-Tract enables companies to grow commercial volumes of medical-grade cannabis without having to obtain a license or invest in developing their own facilities. Companies select a cultivation and payment plan that suits their needs; the cultivation plan may include using Highlands’s genetics or providing their own.
CBD Pharma has contracted for two hectares of Highlands’ Cherry Wine CBD genetics for this season, Cherry Wine is one of the foundational CBD strains, which is widely used because of its high quality. The season is progressing well and harvest is expected in mid-March. In late April, both the smoking quality buds and bulk packed extraction grade product will be ready for export.
CBD Pharma intends to establish (subject to regulatory approval) a propagation facility on land leased from Highlands in order to supply high quality genetics for Highlands, CBD Pharma’s own grow needs and future Canna-Tract partners.
“This partnership proves that Canna-Tract is an attractive offering for those looking to grow medical grade cannabis at scale. We are excited about the opportunity to grow premium flower for CBD Pharma,” concludes Corbett.
